Document text
Principal Investigator: Joseph Patti
Organization: AGILVAX, INC.
Fiscal Year: 2019
Award: $845,852
Funding agency: National Cancer Institute
Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer
immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead
product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting cancer stem cells
(CSC) that is designed for use in combination with existing and emerging therapies. TNBC is extremely
aggressive with high rates of recurrence and overall poor outcomes as compared to other forms of breast
cancer. The average 5-year survival rate for metastatic patients with TNBC is only 26.1%. TNBC is more likely
to occur in women under the age of 40, and the rate of incidence is higher in African-American and Hispanic
populations as compared to Caucasian populations. It is estimated that 30,000 women will be diagnosed with
TNBC in 2017.
AX09 Targets Breast Cancer Stem Cells to Prevent Relapse and Metastasis: With no CSC targeted
therapies currently available, there is a critical need for the development of therapeutics for patients impacted
by TNBC. AX09 is composed of a VLP that displays a specific portion of a protein, xCT, that is overexpressed
in breast cancer stem cells (BCSC) and contributes to chemotherapeutic drug resistance and metastasis.
AX09 is favorably positioned in the emerging market of various treatment approaches targeting TNBC, which
will increasingly segment the patient population by novel biomarkers and molecular targets. Due to their
resistance to radiation and chemotherapies, BCSC represent a reservoir for the relapse, metastatic evolution
and progression after initial treatment. AX09 produces an oligoclonal antibody response against the BCSC
target, xCT, that will eliminate BCSC as a source of recurrence.
Agilvax’s Aims for the Fast-Track SBIR Include Preclinical Work, cGMP Manufacturing and a
Toxicology Study: Agilvax’s goals for this grant are to complete its preclinical work, including upstream and
downstream process development of AX09 based on processes the company successfully used in developing
another VLP-based product. As part of its first goal, Agilvax will strengthen AX09 efficacy by determining the
optimal dosage regimen, confirming efficacy in a second tumor model, and assess the combination of AX09
with other chemotherapeutic agents in planning for the Phase I trial design. Agilvax will proceed with cGMP
production and validation of research and master cell banks in order to complete cGMP manufacturing and
release testing of AX09 drug substance and drug product. Upon the recommendation of Agilvax’s Key Opinion
Leaders in breast cancer, a single nonclinical toxicology study using New Zealand white rabbits is planned.
Terms: <4T1><7S Gamma Globulin><Abraxane><Abscission><African American><Afro American><Afroamerican><After Care><After-Treatment><Aftercare><Age><Antibodies><Antibody Response><Antineoplastic Vaccine><BALB C Mouse><BALB/c><Biological><Black Populations><Breast Cancer><Cancer Patient><Cancer Treatment><Cancer Vaccines><Caucasian><Caucasian Race><Caucasians><Caucasoid><Caucasoid Race><Cell Body><Cell Function><Cell Process><Cell physiology><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chemicals><Clinic><Control Animal><Cyclic GMP><Cystine><Data><Defect><Development><Diagnosis><Disease><Disease Progression><Disorder><Distal><Domestic Rabbit><Dose><Drug resistance><Drug usage><Drugs><ELISA><Early-Stage Clinical Trials><Engineering><Enzyme-Linked Immunosorbent Assay><Equilibrium><Evolution><Excision><Extirpation><Formulation><Generalized Growth><Glutamates><Glutathione><Goals><Grant><Growth><Guanosine Cyclic Monophosphate><Guidelines><Hispanic Populations><Hispanics><Human><IgG><Immunize><Immunoglobulin G><Immunologically Directed Therapy><Immunotherapy><Inbred BALB C Mice><Incidence><Intake><Intramuscular><KO mice><Knock-out Mice><Knockout Mice><L-Cystine><L-Glutamate><Latino Population><Lead><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Measures><Medication><Messenger RNA><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Modeling><Modern Man><Molecular Target><Murine><Mus><Neoplasm Metastasis><Neoplasm Vaccines><Neoplastic Colony-Forming Units><Neoplastic Stem Cells><New Zealand><Normal Cell><Null Mouse><Occidental><Oryctolagus cuniculus><Outcome><Oxidation-Reduction><Pathway interactions><Patients><Pb element><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase 1 Clinical Trials><Phase I Clinical Trials><Population><Position><Positioning Attribute><Primary Neoplasm><Primary Tumor><Process><Property><Proteins><Rabbits><Rabbits Mammals><Radiation><Recommendation><Recurrence><Recurrent><Redox><Regimen><Relapse><Removal><Reproducibility><Research><Resistance><Running><SBIR><SCL Transcription Factor><Safety><Secondary Neoplasm><Secondary Tumor><Site><Small Business Innovation Research><Small Business Innovation Research Grant><Solid Neoplasm><Solid Tumor><Source><Spanish Origin><Stem Cell Leukemia Hematopoietic Transcription Factor><Stem Cell Protein><Subcellular Process><Surgical Removal><Survival Rate><T-Cell Acute Lymphocytic Leukemia 1 Gene><T-cell acute lymphocytic leukemia 1 protein><TAL1><TAL1 Gene Product><TAL1 gene><TCL5><TNBC><Taxotere><Technology><Technology Transfer><Testing><Therapeutic><Tissue Growth><Toxic effect><Toxicities><Toxicology><Tumor Cell><Tumor Stem Cells><Tumor Vaccines><Vaccines><Validation><Virus-like particle><Woman><Work><Xeloda><ages><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><anticancer therapy><antiporter><balance><balance function><base><black American><cGMP><cGMP production><cancer immunotherapy><cancer metastasis><cancer stem cell><cancer therapy><capecitabine><cell bank><cell type><chemotherapeutic agent><chemotherapy><combinatorial><design><designing><developmental><docetaxel><docetaxol><dosage><drug resistant><drug use><drug/agent><flexibility><flexible><gamma-L-Glu-L-Cys-Gly><gamma-L-Glutamyl-L-Cysteinylglycine><glutamatergic><heavy metal Pb><heavy metal lead><hispanic community><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogenic><immunogenicity><immunotherapy for cancer><immunotherapy of cancer><inhibiting antibody><lung metastasis><mRNA><malignant breast neoplasm><malignant breast tumor><malignant stem cell><manufacturing process development><metastasize to the lung><mouse model><murine model><neoplastic cell><new marker><novel><novel biomarker><novel marker><ontogeny><overexpress><overexpression><oxidation reduction reaction><pathway><patient population><phase 1 trial><phase 2 study><phase I protocol><phase I trial><phase II study><post treatment><pre-clinical><pre-clinical development><pre-clinical study><preclinical><preclinical development><preclinical study><prevent><preventing><programs><pulmonary metastasis><resection><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><response><self-renew><self-renewal><stem cell therapeutics><stem cell therapy><stem cell treatment><stem cell-based treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic resistance><therapeutic target><therapy resistant><treatment resistance><trial design><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor cell metastasis><tumor growth><vaccine for cancer><virus-like nanoparticles><viruslike particle><white race>